close
Add to watchlist
Array BioPharma Inc (ARRY) Healthcare, Biotechnology & Drugs
Array BioPharma, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted small molecule drugs to treat cancer, inflammatory diseases, and pain in North America, Europe, and Asia Pacific. Its development programs primarily include ARRY-797, a p38 inhibitor and pan-cytokine modulator for inflammation and pain; ARRY-162, a MEK inhibitor for inflammation; ARRY-614, a p38/Tie 2 dual inhibitor for cancer and/or inflammation; ARRY-543, an ErbB family (EFGR / ErbB-2) inhibitor for cancer; ARRY-520, a KSP inhibitor for cancer; and ARRY-380, an ErbB-2 inhibitor for cancer. The company has collaborations with AstraZeneca PLC, which licensed three MEK inhibitors for cancer; Genentech, Inc. to develop two cancer programs; and Celgene Corporation focusing on the discovery, development, and commercialization of novel therapeutics in cancer and inflammation. Array BioPharma was founded in 1998 and is headquartered in Boulder, Colorado.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 3.21 |
| Volume | (mio) 1.05 |
| Volume Avg | 728366 |
| 52 Week High | 3.41 |
| 52 Week Low | 1.58 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.71 |
| EPS change Q/Q | -13.04% |
| EPS change Q/Q Yr ago | -33.33% |
| EPS change Q/Q next Q est | -53.85% |
| EPS change Y/Y | -94.62% |
| REV change Q/Q | 7.88% |
| REV change Q/Q Yr ago | -3.26% |
| EPS next Q est | -0.13 |
| EPS next Y est | -0.62 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |